1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Most relevant
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Delayed London Stock Exchange  -  11:35 2022-08-16 am EDT
10968.00 GBX   +0.05%
08/16Australia biotech giant CSL reports profit dip, flags cost spiral
RE
08/16Lynparza in combination with abiraterone granted Priority Review in the US for patients with metastatic castration-resistant prostate cancer
AQ
08/16AstraZeneca Sues Former Executive to Prevent Potential Therapy Data Leak to Rival GSK
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about ASTRAZENECA PLC
08/16Australia biotech giant CSL reports profit dip, flags cost spiral
RE
08/16Lynparza in combination with abiraterone granted Priority Review in the US for patient..
AQ
08/16AstraZeneca Sues Former Executive to Prevent Potential Therapy Data Leak to Rival GSK
MT
08/16AstraZeneca Granted FDA Priority Review for Prostate Cancer Combination Therapy
MT
08/16LYNPARZA® (olaparib) in combination with abiraterone granted Priority Review in the US ..
BU
08/16ASTRAZENECA : Lynparza in combination with abiraterone granted Priority Review in the US f..
PU
08/16UK's Trade Performance With US Weakens on Strong Dollar, Fuel Imports
DJ
08/16FTSE 100 Rises as Strong BHP Results Help Lift Miners
DJ
08/16Pound Unmoved After Jobs Data; Latest Inflation Print in Focus
DJ
08/16FTSE 100 to Open Higher; Jobs Data Reveals 4.7% Wage Growth
DJ
08/16AstraZeneca, Merck & Co.'s Prostate Cancer Drug Wins US FDA's Priority Review Tag
MT
08/16Unichem Laboratories Gets US FDA Approval for Generic Mental Disorder Drug
MT
08/16AstraZeneca's Lynparza Supplemental New Drug Application Granted Priority Review by FDA
DJ
08/15ADRs End Mixed, Amarin and AstraZeneca Trade Actively
DJ
08/15ASTRAZENECA : Enhertu significantly delayed disease progression in DESTINY-Breast02 Phase ..
PU
08/15Enhertu significantly delayed disease progression in DESTINY-Breast02 Phase III trial ..
AQ
08/15Serum Institue of India's Poonawalla expects Omicron-specific vaccine in 6 months -NDTV
RE
08/15Guardant Health Receives FDA Approval for Guardant360 CDx as Companion Diagnostic for D..
AQ
08/15ENHERTU Significantly Delayed Disease Progression in DESTINYBreast02 Phase 3 Trial Vers..
AQ
08/15Enhertu approved in the US as the first HER2-directed therapy for patients with previou..
AQ
08/15FTSE 100 ends higher as AstraZeneca offsets commodity losses
RE
08/15AstraZeneca Tops FTSE 100 Risers on Drug Progress
DJ
08/15European shares edge higher on defensive lift, weak China data stokes worries
RE
08/15AstraZeneca, Daiichi Sankyo Say Their Breast Cancer Drug Delayed Disease Progression in..
MT
08/15FTSE 100 Rises as AstraZeneca Gains on Positive Trial Result
DJ
08/15FTSE 100 up 0.2%, lifted by Astrazeneca
MS
08/15LONDON STOCK EXCHANGE : FTSE 100 inches higher as AstraZeneca counters China worries
RE
08/15EUROPE : European shares edge higher; weak China data stokes worries
RE
08/15AstraZeneca-Daiichi's breast cancer drug improves survival in study
RE
08/15Enhertu Significantly Delayed Breast Cancer Progression in Trial, AstraZeneca Says
DJ
08/15AstraZeneca's Enhertu Prolongs Progression-free Survival in Late-stage Breast Cancer St..
MT
08/15ENHERTU® Significantly Delayed Disease Progression in DESTINY-Breast02 Phase 3 Trial Ve..
CI
08/12Seagen loses arbitration against Daiichi Sankyo over drug technology
RE
08/12Seagen loses arbitration ruling against Daiichi Sankyo
RE
08/12European Stocks Close Higher After UK GDP, Eurozone Industrial Production Data
MT
08/12Sanofi Says First Patient Enrolled in Study to Investigate Protection Against Respirato..
MT
08/12Guardant Health Says FDA Approved Liquid Biopsy Test as Companion Diagnostic for Lung C..
MT
08/12Enhertu approved in the US as the first HER2-directed therapy for patients with previou..
AQ
08/12ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directe..
BU
08/12ASTRAZENECA : Enhertu approved in the US as the first HER2-directed therapy for patients w..
PU
08/12AstraZeneca, Daiichi Sankyo Receive FDA Approval for Lung Cancer Drug
MT
08/12AstraZeneca's Lung Cancer Drug Secures US FDA's Nod
MT
08/12Chasing green goals, corporations push car fleet managers toward EVs
RE
08/12AstraZeneca, Daiichi's Enhertu Approved by the FDA for Lung Cancer Treatment
DJ
08/11Daiichi Sankyo and Astrazeneca’s ENHERTU® Approve in the U.S. as the First HER2 Di..
CI
08/11Acquisition of TeneoTwo for its clinical-stage T-cell engager completed
AQ
08/11European ADRs Move Lower in Thursday Trading
MT
08/11ASTRAZENECA : Acquisition of TeneoTwo for its clinical-stage T-cell engager completed - Fo..
PU
08/11AstraZeneca Closes Up to $1.3 Billion TeneoTwo Acquisition
MT
08/11ASTRAZENECA : Acquisition of TeneoTwo for its clinical-stage T-cell engager completed
PU
08/11AstraZeneca PLC completed the acquisition of TeneoTwo, Inc. from TBio, LLC and others.
CI
08/11ASTRAZENECA PLC : Ex-dividend day for interim dividend
FA
08/10India to start COVID mix-and-match booster vaccines on Friday
RE
08/10POSEIDON Phase III post-hoc exploratory analyses presented at WCLC 2022
AQ
08/09ADRs End Mixed
DJ
08/09ASTRAZENECA : Gets a Buy rating from JP Morgan
MD
08/09AstraZeneca Reports Promising Data From Lung Cancer Trial
DJ
08/09AstraZeneca JV's Non-small Cell Lung Cancer Drug Show Favorable Results On Trial
MT
08/08ADRs End Mixed; Amarin, AstraZeneca Trade Actively
DJ
08/08Transcenta Hires Former AstraZeneca Exec as New Chief Medical Officer
MT
08/08Tagrisso plus savolitinib demonstrated 49% objective response rate in lung cancer patie..
AQ
08/08ASTRAZENECA : Gets a Buy rating from JP Morgan
MD
08/08TAGRISSO® plus savolitinib demonstrated 49% objective response rate in lung cancer pati..
BU
08/08ASTRAZENECA : Enhertu approved in the US as the first HER2-directed therapy for patients w..
PU
08/08AstraZeneca Says Lung Cancer Combination Therapy Showed 49% Objective Response Rate
MT
08/08AstraZeneca's Lung Cancer Drug Combo Shows 49% Objective Response Rate in Mid-stage Tri..
MT
08/08Enhertu approved in the US as the first HER2-directed therapy for patients with HER2-lo..
AQ
08/08HUTCHMED Limited and AstraZeneca PLC Announce Preliminary Results from SAVANNAH Phase I..
CI
08/08Climate change puts Lyme disease in focus for France's Valneva after COVID blow
RE
08/08AstraZeneca's Enhertu Breast Cancer Treatment Approved for Use in US
DJ
08/07AstraZeneca's Breast Cancer Drug Wins US FDA's First-in-class Approval
MT
08/06Daiichi Sankyo and AstraZeneca’s Enhertu® Receives Approval in the U.S. as the Fir..
CI
08/05ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directe..
BU
08/05ASTRAZENECA : Enhertu approved in the US as the first HER2-directed therapy for patients w..
PU
08/05CALQUENCE® (acalabrutinib) tablet formulation approved in the US across current indicat..
BU
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on ASTRAZENECA PLC